vs
波士顿科学（BSX）与Block, Inc.（XYZ）财务数据对比。点击上方公司名可切换其他公司
Block, Inc.的季度营收约是波士顿科学的1.2倍（$6.3B vs $5.2B），波士顿科学净利率更高（25.7% vs 1.9%，领先23.9%），波士顿科学同比增速更快（11.6% vs 3.6%），过去两年波士顿科学的营收复合增速更高（12.4% vs 2.4%）
波士顿科学是一家美国跨国生物科技与生物医学工程企业，专注于介入医学领域医疗设备的研发生产，产品覆盖介入心内科、介入放射科、神经调控、肿瘤、泌尿、妇科、内镜、心脏及血管外科等多个专科诊疗场景。
Block, Inc.是美国科技企业，面向消费者与商户提供金融服务，由杰克·多尔西于2009年创立，是美国销售点系统领域的市场领导者。截至2024年，平台服务5700万用户及400万商户，年支付处理规模达2410亿美元。
BSX vs XYZ — 直观对比
营收规模更大
XYZ
是对方的1.2倍
$5.2B
营收增速更快
BSX
高出7.9%
3.6%
净利率更高
BSX
高出23.9%
1.9%
两年增速更快
BSX
近两年复合增速
2.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.2B | $6.3B |
| 净利润 | $1.3B | $115.8M |
| 毛利率 | 69.5% | 45.9% |
| 营业利润率 | — | 7.8% |
| 净利率 | 25.7% | 1.9% |
| 营收同比 | 11.6% | 3.6% |
| 净利润同比 | 99.0% | -94.1% |
| 每股收益（稀释后） | $0.90 | $0.19 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BSXXYZ
| Q1 26 | $5.2B | — | ||
| Q4 25 | $5.3B | $6.3B | ||
| Q3 25 | $5.1B | $6.1B | ||
| Q2 25 | $5.1B | $6.1B | ||
| Q1 25 | $4.7B | $5.8B | ||
| Q4 24 | $4.6B | $6.0B | ||
| Q3 24 | $4.2B | $6.0B | ||
| Q2 24 | $4.1B | $6.2B |
净利润BSXXYZ
| Q1 26 | $1.3B | — | ||
| Q4 25 | $670.0M | $115.8M | ||
| Q3 25 | $755.0M | $461.5M | ||
| Q2 25 | $795.0M | $538.5M | ||
| Q1 25 | $672.0M | $189.9M | ||
| Q4 24 | $563.0M | $1.9B | ||
| Q3 24 | $468.0M | $283.8M | ||
| Q2 24 | $322.0M | $195.3M |
毛利率BSXXYZ
| Q1 26 | 69.5% | — | ||
| Q4 25 | 69.6% | 45.9% | ||
| Q3 25 | 69.9% | 43.5% | ||
| Q2 25 | 67.7% | 41.9% | ||
| Q1 25 | 68.8% | 39.7% | ||
| Q4 24 | 67.8% | 38.3% | ||
| Q3 24 | 68.8% | 37.6% | ||
| Q2 24 | 69.2% | 36.3% |
营业利润率BSXXYZ
| Q1 26 | — | — | ||
| Q4 25 | 15.6% | 7.8% | ||
| Q3 25 | 20.7% | 6.7% | ||
| Q2 25 | 16.2% | 8.0% | ||
| Q1 25 | 19.8% | 5.7% | ||
| Q4 24 | 14.8% | 0.2% | ||
| Q3 24 | 17.4% | 5.4% | ||
| Q2 24 | 12.6% | 5.0% |
净利率BSXXYZ
| Q1 26 | 25.7% | — | ||
| Q4 25 | 12.7% | 1.9% | ||
| Q3 25 | 14.9% | 7.5% | ||
| Q2 25 | 15.7% | 8.9% | ||
| Q1 25 | 14.4% | 3.3% | ||
| Q4 24 | 12.3% | 32.3% | ||
| Q3 24 | 11.1% | 4.7% | ||
| Q2 24 | 7.8% | 3.2% |
每股收益（稀释后）BSXXYZ
| Q1 26 | $0.90 | — | ||
| Q4 25 | $0.45 | $0.19 | ||
| Q3 25 | $0.51 | $0.74 | ||
| Q2 25 | $0.53 | $0.87 | ||
| Q1 25 | $0.45 | $0.30 | ||
| Q4 24 | $0.38 | $3.06 | ||
| Q3 24 | $0.32 | $0.45 | ||
| Q2 24 | $0.22 | $0.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $6.6B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $22.2B |
| 总资产 | — | $39.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BSXXYZ
| Q1 26 | — | — | ||
| Q4 25 | $2.0B | $6.6B | ||
| Q3 25 | $1.3B | $8.3B | ||
| Q2 25 | $534.0M | $6.4B | ||
| Q1 25 | $725.0M | $7.1B | ||
| Q4 24 | $414.0M | $8.1B | ||
| Q3 24 | $2.5B | $8.3B | ||
| Q2 24 | $2.9B | $7.8B |
总债务BSXXYZ
| Q1 26 | — | — | ||
| Q4 25 | $11.1B | — | ||
| Q3 25 | $11.1B | $7.3B | ||
| Q2 25 | $11.1B | $5.1B | ||
| Q1 25 | $10.5B | $5.1B | ||
| Q4 24 | $9.0B | $6.1B | ||
| Q3 24 | $9.2B | $6.1B | ||
| Q2 24 | $9.0B | $6.1B |
股东权益BSXXYZ
| Q1 26 | — | — | ||
| Q4 25 | $24.2B | $22.2B | ||
| Q3 25 | $23.4B | $22.5B | ||
| Q2 25 | $22.4B | $22.2B | ||
| Q1 25 | $22.2B | $21.5B | ||
| Q4 24 | $21.8B | $21.3B | ||
| Q3 24 | $20.7B | $19.9B | ||
| Q2 24 | $20.4B | $19.3B |
总资产BSXXYZ
| Q1 26 | — | — | ||
| Q4 25 | $43.7B | $39.5B | ||
| Q3 25 | $42.7B | $39.2B | ||
| Q2 25 | $41.6B | $36.9B | ||
| Q1 25 | $40.1B | $36.4B | ||
| Q4 24 | $39.4B | $36.8B | ||
| Q3 24 | $38.1B | $36.4B | ||
| Q2 24 | $37.1B | $37.5B |
负债/权益比BSXXYZ
| Q1 26 | — | — | ||
| Q4 25 | 0.46× | — | ||
| Q3 25 | 0.48× | 0.32× | ||
| Q2 25 | 0.50× | 0.23× | ||
| Q1 25 | 0.47× | 0.24× | ||
| Q4 24 | 0.41× | 0.29× | ||
| Q3 24 | 0.45× | 0.31× | ||
| Q2 24 | 0.44× | 0.32× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $621.0M |
| 自由现金流经营现金流 - 资本支出 | — | $579.8M |
| 自由现金流率自由现金流/营收 | — | 9.3% |
| 资本支出强度资本支出/营收 | — | 0.7% |
| 现金转化率经营现金流/净利润 | — | 5.36× |
| 过去12个月自由现金流最近4个季度 | — | $2.4B |
8季度趋势，按日历期对齐
经营现金流BSXXYZ
| Q1 26 | — | — | ||
| Q4 25 | $1.4B | $621.0M | ||
| Q3 25 | $1.3B | $1.5B | ||
| Q2 25 | $1.3B | $374.3M | ||
| Q1 25 | $541.0M | $133.3M | ||
| Q4 24 | $1.5B | $13.8M | ||
| Q3 24 | $1.0B | $684.8M | ||
| Q2 24 | $813.0M | $519.4M |
自由现金流BSXXYZ
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | $579.8M | ||
| Q3 25 | $1.2B | $1.4B | ||
| Q2 25 | $1.1B | $343.0M | ||
| Q1 25 | $354.0M | $101.5M | ||
| Q4 24 | $1.2B | $-13.2M | ||
| Q3 24 | $823.0M | $628.2M | ||
| Q2 24 | $658.0M | $481.0M |
自由现金流率BSXXYZ
| Q1 26 | — | — | ||
| Q4 25 | 19.2% | 9.3% | ||
| Q3 25 | 22.9% | 22.9% | ||
| Q2 25 | 22.3% | 5.7% | ||
| Q1 25 | 7.6% | 1.8% | ||
| Q4 24 | 25.8% | -0.2% | ||
| Q3 24 | 19.6% | 10.5% | ||
| Q2 24 | 16.0% | 7.8% |
资本支出强度BSXXYZ
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | 0.7% | ||
| Q3 25 | 3.6% | 0.8% | ||
| Q2 25 | 3.1% | 0.5% | ||
| Q1 25 | 4.0% | 0.6% | ||
| Q4 24 | 6.1% | 0.4% | ||
| Q3 24 | 4.3% | 0.9% | ||
| Q2 24 | 3.8% | 0.6% |
现金转化率BSXXYZ
| Q1 26 | — | — | ||
| Q4 25 | 2.04× | 5.36× | ||
| Q3 25 | 1.78× | 3.14× | ||
| Q2 25 | 1.62× | 0.70× | ||
| Q1 25 | 0.81× | 0.70× | ||
| Q4 24 | 2.59× | 0.01× | ||
| Q3 24 | 2.14× | 2.41× | ||
| Q2 24 | 2.52× | 2.66× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BSX
| Cardiovascular | $3.1B | 59% |
| Endoscopy | $673.0M | 13% |
| Urology | $633.0M | 12% |
| Other | $386.0M | 7% |
| Neuromodulation | $271.0M | 5% |
| LACA | $155.0M | 3% |
XYZ
| US | $5.7B | 91% |
| Non Us | $560.9M | 9% |
